General Partner
- geert-jan.mulder@forbion.com
- Download vCard 
Geert-Jan is General Partner and joined the ABN AMRO Capital Life Sciences team in 2001.
Prior to working in the VC industry Geert-Jan was Clinical Research Manager for The Netherlands for Byk Gulden (now Nycomed), where his department dealt with the design and execution of numerous phase I/IIa, IIb, IIIa and IIIb clinical trials in the fields of Gastroenterology, Respiratory Medicine (asthma and COPD), Intensive Care Medicine and Imaging. He was a Member of the Global Medical Marketing group of the Respiratory Franchise and involved in the line extension program for Pantozol (pantoprazole). Prior to joining Byk Gulden he was with Searle (now Pfizer) working in the field of Arthritis & Pain as a Medical Adviser, being involved in the clinical development as well as local and European advocate development in the pre-launch roll-out for Celebrex (celecoxib). Geert-Jan’s extensive clinical development experience is an invaluable asset to the Forbion team and its portfolio Companies.
Geert-Jan serves on the Board of Exosome Diagnostics, Promedior.,PanGenetics, Provesica and bluebird. He was also on the Board of Transave (acquired by Insmed in 2010).
Geert-Jan received his Medical Degree from the University of Utrecht in the Netherlands. During and after his internships he spent two years as a clinician in Obstetrics and Gynaecology at the University Medical Center of Utrecht (UMC). In 2001, Geert-Jan was awarded his Registration as Pharmaceutical Physician.
